SciSparc announced that NeuroThera Labs, a clinical-stage pharmaceutical company focused on developing novel for central nervous system disorders, was granted a U.S. patent for its proprietary combination of antimicrobials and cannabinoids.
This patent covers compositions and methods of potentiating antimicrobials, specifically designed to enhance the efficacy of existing antibiotics against resistant bacterial strains.
The patented technology combines well-established antibiotics—many of which have been on the market for decades—with cannabinoids such as THC and Cannabidiol (CBD), and in certain embodiments, N-acylethanolamines like palmitoylethanolamide (PEA). This synergistic approach, which used NeuroThera’s combination of antimicrobials and cannabinoids, demonstrated in pre-clinical studies, enhances antimicrobial activity, potentially restoring the effectiveness of antibiotics that are ineffective as monotherapy against resistant Gram-positive pathogens, such as Methicillin-resistant Staphylococcus aureus (“MRSA”). When administered in combination with cannabinoids, the platform leverages the extensive long-term safety data of these antibiotics to help minimize risk, potentially offering an effective, safe, and affordable therapeutic solution.
This patent family is based on preclinical studies conducted to evaluate the antimicrobial effects of cannabinoids when combined with antibiotics in well-established, regulatory-compliant models.
The "antimicrobial-sparing" effect shown in pre-clinical studies using NeuroThera's proprietary combination may eliminate the constant requirements for new antibiotics to combat resistant microbial strains, helping mitigate serious side effects such as resistance development, organ toxicity, and gastrointestinal issues, all while capitalizing on the proven safety profiles of long-marketed antibiotics.
